Overview

Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal in Patients With Intermittent Claudication

Status:
TERMINATED

Trial end date:
2017-02-08

Target enrollment:

Participant gender:

Summary

The study is designed to compare the efficacy and safety of once daily PMR treatment with twice daily Pletaal treatment in patients with intermittent claudication caused by peripheral arterial disease and are currently treated with cilostazol of any strength and any dosing frequency.

Phase:

PHASE3

Details

Lead Sponsor:

Genovate Biotechnology Co., Ltd.,

Treatments:

Cilostazol